PPARGamma in Sepsis-Induced Immunosuppression
PPARGamma in Sepsis-Induced Immunosuppression
批准号:
7107163
负责人:
RAJU C REDDY
金额:
$13.27万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-30 至 2008-02-29
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Patients with sepsis are highly susceptible to the development of nosocomial
infection, particularly bacterial infection of the lung. While the exact
mechanism(s) that contribute to sepsis-mediated immunosuppression remains
unclear, dysregulation of monocyte/macrophage function is believed to play an
important role in these phenomena. Recently, peroxisome proliferator-activated
receptor-gamma (PPARy), a member of the nuclear receptor superfamily
of ligand-dependent transcription factors, has been shown to inhibit the
expression of inflammatory mediators from monocytes/macrophages and other
leukocyte populations. The hypothesis of this proposal is that sepsis induced
immunosuppression is mediated, in part, by PPARy. Furthermore, we postulate
that inhibition of this ligand dependent transcription factor will reverse
sepsis-induced changes in alveolar macrophage function, resulting in augmented
lung antibacterial host defense.
A murine model of cecal ligation and puncture (resulting in an abdominal
sepsis syndrome) will be utilized to assess the following Specific Aims: I) to
determine the time course and magnitude of PPARy expression in lung during the
evolution of murine abdominal sepsis; II) to determine the functional
significance of PPARy activation on effector cell functions of primary murine
alveolar macrophages or murine alveolar macrophage cell lines; III) to
identify the endogenous signals that regulate PPARy expression during the
evolution of murine abdominal sepsis; and IV) to determine the effect of
inhibition of PPARy on sepsis- induced alterations in alveolar macrophage
function ex-vivo and susceptibility to Pseudomonas pneumonia in-vivo.
Performance of the studies outlined will help define the role of PPARy as a
mediator of sepsis-induced alveolar macrophage dysfunction, and may lead to
the development of novel therapies to be employed in the treatment of patients
with sepsis.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1186/1465-9921-8-90
发表时间:
2007-12-04
期刊:
Respiratory research
影响因子:
5.8
作者:
[Narala VR, Ranga R, Smith MR, Berlin AA, Standiford TJ, Lukacs NW, Reddy RC]
通讯作者:
Reddy RC
DOI:
10.1016/j.pep.2006.08.013
发表时间:
2007-03
期刊:
Protein expression and purification
影响因子:
1.6
作者:
[P. K. Reddy;Srinivasa G Reddy;V. Narala;S. Majee;Sudhakar Konda;S. Gunwar;Raju C Reddy]
通讯作者:
P. K. Reddy;Srinivasa G Reddy;V. Narala;S. Majee;Sudhakar Konda;S. Gunwar;Raju C Reddy
DOI:
10.1016/j.jaci.2008.12.018
发表时间:
2009-03
期刊:
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
影响因子:
14.2
作者:
[Khan, Farah I., Reddy, Raju C., Baptist, Alan P.]
通讯作者:
Baptist, Alan P.
DOI:
--
发表时间:
2009-04
期刊:
Gene therapy & molecular biology
影响因子:
--
作者:
[V. Narala;Monica R. Smith;R. K. Adapala;Rajesh Ranga;K. Panati;B. Moore;T. Leff;V. D. Reddy;A. K. Kondapi;Raju C Reddy]
通讯作者:
V. Narala;Monica R. Smith;R. K. Adapala;Rajesh Ranga;K. Panati;B. Moore;T. Leff;V. D. Reddy;A. K. Kondapi;Raju C Reddy
Nur77: Novel Mechanistic Insights and Activation in COPD
-
批准号:10513286
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:RAJU C REDDY
-
依托单位:
Airway Epithelial Cell Farnesoid X Receptor in COPD Pathophysiology
-
批准号:9770704
-
项目类别:
-
资助金额:$39.13万
-
财政年份:2017
-
负责人:RAJU C REDDY
-
依托单位:
PPAR-delta as a Novel Therapeutic Target in Asthma
-
批准号:9155974
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2016
-
负责人:RAJU C REDDY
-
依托单位:
PPAR-delta as a Novel Therapeutic Target in Asthma
-
批准号:9282803
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2016
-
负责人:RAJU C REDDY
-
依托单位:
Role of PPAR-gamma in Smoking-induced COPD Progression and Steroid Resistance
-
批准号:8333651
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:RAJU C REDDY
-
依托单位:
Role of PPAR-gamma in Smoking-induced COPD Progression and Steroid Resistance
-
批准号:8803249
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:RAJU C REDDY
-
依托单位:
Role of PPAR-gamma in Smoking-induced COPD Progression and Steroid Resistance
-
批准号:8680001
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:RAJU C REDDY
-
依托单位:
Nitrated Fatty Acids, Novel Anti-inflammatory Mediator in Allergic Airway Disease
-
批准号:8243538
-
项目类别:
-
资助金额:$31.95万
-
财政年份:2009
-
负责人:RAJU C REDDY
-
依托单位:
Nitrated Fatty Acids, Novel Anti-inflammatory Mediators in Allergic Airway Diseas
-
批准号:7837506
-
项目类别:
-
资助金额:$9.0万
-
财政年份:2009
-
负责人:RAJU C REDDY
-
依托单位:
Nitrated Fatty Acids, Novel Anti-inflammatory Mediators in Allergic Airway Diseas
-
批准号:7654265
-
项目类别:
-
资助金额:$38.35万
-
财政年份:2009
-
负责人:RAJU C REDDY
-
依托单位:
Nitrated Fatty Acids, Novel Anti-inflammatory Mediators in Allergic Airway Diseas
-
批准号:8051830
-
项目类别:
-
资助金额:$32.28万
-
财政年份:2009
-
负责人:RAJU C REDDY
-
依托单位:
Nitrated Fatty Acids, Novel Anti-inflammatory Mediator in Allergic Airway Disease
-
批准号:8448650
-
项目类别:
-
资助金额:$31.58万
-
财政年份:2009
-
负责人:RAJU C REDDY
-
依托单位:
Nitrated Fatty Acids, Novel Anti-inflammatory Mediators in Allergic Airway Diseas
-
批准号:8112804
-
项目类别:
-
资助金额:$32.28万
-
财政年份:2009
-
负责人:RAJU C REDDY
-
依托单位:
Nitrated Fatty Acids, Novel Anti-inflammatory Mediators in Allergic Airway Diseas
-
批准号:8113641
-
项目类别:
-
资助金额:$10.68万
-
财政年份:2009
-
负责人:RAJU C REDDY
-
依托单位:
Curcumin: A Multi-Mechanism HIV Microbicide
-
批准号:8117439
-
项目类别:
-
资助金额:$17.53万
-
财政年份:2008
-
负责人:RAJU C REDDY
-
依托单位:
Curcumin: A Multi-Mechanism HIV Microbicide
-
批准号:7513497
-
项目类别:
-
资助金额:$19.26万
-
财政年份:2008
-
负责人:RAJU C REDDY
-
依托单位:
PPARGamma in Sepsis-Induced Immunosuppression
-
批准号:6788108
-
项目类别:
-
资助金额:$13.27万
-
财政年份:2002
-
负责人:RAJU C REDDY
-
依托单位:
PPARGamma in Sepsis-Induced Immunosuppression
-
批准号:6944326
-
项目类别:
-
资助金额:$13.27万
-
财政年份:2002
-
负责人:RAJU C REDDY
-
依托单位:
PPARGamma in Sepsis-Induced Immunosuppression
-
批准号:6666719
-
项目类别:
-
资助金额:$13.27万
-
财政年份:2002
-
负责人:RAJU C REDDY
-
依托单位:
PPARGamma in Sepsis-Induced Immunosuppression
-
批准号:6465343
-
项目类别:
-
资助金额:$13.27万
-
财政年份:2002
-
负责人:RAJU C REDDY
-
依托单位:
海外基金